Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
27 janv. 2023 08h00 HE
|
Senti Biosciences, Inc.
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other...
BioCardia Letter to Shareholders
22 déc. 2022 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and...
BioCardia Announces $3.6 Million Private Placement of Common Stock
15 déc. 2022 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and...
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
10 nov. 2022 07h55 HE
|
Senti Biosciences, Inc.
- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for...
BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results
09 nov. 2022 16h05 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting
03 nov. 2022 09h05 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Announces New Employment Inducement Grants
28 oct. 2022 16h05 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Correction: Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners
04 oct. 2022 09h21 HE
|
Dark Horse Consulting Group
Walnut Creek, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView...
Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners
04 oct. 2022 08h12 HE
|
Dark Horse Consulting Group
Walnut City, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView Capital...
Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference
20 sept. 2022 16h02 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...